-
Loading

LIVER - NON HEPATITIS & Cannabis studies completed

Overview

Like any other medicinal plant, cannabis has intrinsic properties that allow it to produce both beneficial effects and undesired side effects.


Some of these side effects are cognitive, such as the impairment of the short-term memory or the potential to trigger psychotic episodes in susceptible individuals. (Sensi Seeds published an interesting article on Cannabis and Episodic Memory. To read it click here, ed)


The negative physical side effects of cannabis include an increase in oxygen consumption by the heart tissues and, as we shall see in this article, the capacity to accelerate the progression of fibrosis in individuals suffering chronic Hepatitis C, if cannabis is consumed regularly and not just on a sporadic basis.


In cirrhotic human livers, there is a higher number of CB1 Cannabinoid receptors, which indicates that the Endocannabinoid system is involved in the physiopathology of this clinical picture. (You can read more about the Cannabinoid Science and the Endocannabinoid System here, ed)

Science and Research

1955 - Study ~ HEMP AS A MEDICAMENT : Importance of hemp seeds in the tuberculosis therapy

2002 - Study ~ Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

2003 - Study ~ A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation

2003 - Study ~ The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis.

2003 - Study ~ Pathogenesis and treatment of pruritus in patients with cholestasis

2004 - Study ~ Treatment of the Pruritus of Cholestasis.

2005 - Study ~ The endocannabinoid system in chronic liver disease

2005 - Study ~ (Marijuana/Hash) Endocannabinoids and liver disease - review

2005 - Study ~ Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

2005 - Study ~ Roles of anandamide in the hepatic microcirculation in cirrhotic rats

2005 - Study ~ The Ffa Receptor Gpr40 Links Hyperinsulinemia, Hepatic Steatosis, and Impaired Glucose Homeostasis in Mouse.

2005 - Study ~ Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

2007 - Study ~ CB2 receptors as new therapeutic targets for liver diseases

2007 - Study ~ Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

2007 - Study ~ Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase

2007 - Study ~ Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats

2007 - Study ~ Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

2007 - Study ~ Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation

2007 - Study ~ Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury

2007 - Study ~ Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.

2008 - Study ~ Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis

2008 - Study ~ CB2 receptors as new therapeutic targets for liver diseases.

2008 - Study ~ Role of cannabinoids in chronic liver diseases

2008 - Study ~ Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver

2008 - Study ~ Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis

2008 - Study ~ Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases

2008 - Study ~ Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis

2008 - Study ~ Endocannabinoids and Liver Disease. V. Endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis

2008 - Study ~ Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats

2008 - Study ~ Endocannabinoids and the Control of Energy Homeostasis

2008 - Study ~ Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

2008 - Study ~ Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning

2008 - Study ~ Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice.

2008 - Study ~ Endocannabinoids in liver disease and hepatic encephalopathy.

2008 - Study ~ The endocannabinoid system as a novel target for the treatment of liver fibrosis

2008 - Study ~ Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

2009 - Study - Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress

2009 - Study - Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation

2009 - Study ~ Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis

2009 - Study ~ Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

2009 - Study ~ Cannabinoids as novel anti-inflammatory drugs.

2009 - Study ~ Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress.

2009 - Study ~ Science: Oral intake of a cannabinoid together with a meal improved bioavailability by avoiding first-pass metabolism

2009 - Study ~ The role of CB2 cannabinoid receptor and Leptin in hepatic fibrosis via lymphocyte alterations and HSC phagocytosis

2009 - Study ~ Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.

2010 - Study ~ Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice.

2010 - Study ~ Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation.

2010 - Study ~ Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.

2010 - Study ~ Role of the endocannabinoid system in alcoholic liver disease.

2010 - Study ~ Endogenous cannabinoids in liver disease: Many darts for a single target

2011 - Study ~ Endocannabinoids in liver disease.

2011 - Study ~ Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis.

2011 - Study ~ Cannabidiol, a Major Phytocannabinoid, as a Potent Atypical Inhibitor for Cytochrome P450 2D6.

2011 - Study ~ Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats.

2011 - Study ~ Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.

2011 - Study ~ Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and cell death

2011 - Study ~ Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver

2011 - Study ~ Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice.

2011 - Study ~ Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.

2011 - Study ~ Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.

2011 - Study ~ Δ(8) -Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB(2) receptors.

2011 - Study ~ Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver.

2011 - Study ~ A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury.

2011 - Study ~ Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.

2011 - Study ~ Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats.

2011 - News ~ Cannabis Compound Induces Death Of Cells Associated With Liver Fibrosis

2011 - News ~ Marijuana Compound Improves Brain And Liver Function In Animal Model Of Hepatic Encephalopathy

2012 - Study ~ Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver

2012 - Study ~ Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.

2012 - Study ~ Δ(8) -Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB(2) receptors.

2012 - Study ~ The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria.

2012 - Study ~ Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems

Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation

Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM 
Research Support, Non-U.S. Gov't]
Journal of Hepatol 2009 Sep; 51(3):528-34.

BACKGROUND/AIMS: The endocannabinoid system in mice plays a role in models of human cirrhosis and hepatic encephalopathy (HE), induced by a hepatotoxin. We report now the therapeutic effects of cannabidiol (CBD), a non-psychoactive constituent of Cannabis sativa, on HE caused by bile duct ligation (BDL), a model of chronic liver disease.


METHODS: CBD (5mg/kg; i.p.) was administered over 4weeks to mice that had undergone BDL.
RESULTS: Cognitive function in the eight arm maze and the T-maze tests, as well as locomotor function in the open field test were impaired by the ligation and were improved by CBD. BDL raised hippocampal expression of the TNF-alpha-receptor 1 gene, which was reduced by CBD. However, BDL reduced expression of the brain-derived neurotrophic factor (BDNF) gene, which was increased by CBD. The effects of CBD on cognition, locomotion and on TNF-alpha receptor 1 expression were blocked by ZM241385, an A(2)A adenosine receptor antagonist. BDL lowers the expression of this receptor.


CONCLUSIONS: The effects of BDL apparently result in part from down-regulation of A(2)A adenosine receptor. CBD reverses these effects through activation of this receptor, leading to compensation of the ligation effect.


Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress

 

Comelli F, Bettoni I, Colleoni M, Giagnoni G, Costa B 

Phytother Res 2009 May 13.

 

Neuropathy is the most common complication of diabetes and it is still considered to be relatively refractory to most of the analgesics.

 

The aim of the present study was to explore the antinociceptive effect of a controlled cannabis extract (eCBD) in attenuating diabetic neuropathic pain. Repeated treatment with cannabis extract significantly relieved mechanical allodynia and restored the physiological thermal pain perception in streptozotocin (STZ)-induced diabetic rats without affecting hyperglycemia.

 

In addition, the results showed that eCBD increased the reduced glutathione (GSH) content in the liver leading to a restoration of the defence mechanism and significantly decreased the liver lipid peroxidation suggesting that eCBD provides protection against oxidative damage in STZ-induced diabetes that also strongly contributes to the development of neuropathy.

 

Finally, the nerve growth factor content in the sciatic nerve of diabetic rats was restored to normal following the repeated treatment with eCBD, suggesting that the extract was able to prevent the nerve damage caused by the reduced support of this neurotrophin.

 

These findings highlighted the beneficial effects of cannabis extract treatment in attenuating diabetic neuropathic pain, possibly through a strong antioxidant activity and a specific action upon nerve growth factor.

 

Copyright (c) 2009 John Wiley & Sons, Ltd.

 

 

 top